

# The ACT-Accelerator

The plan, progress & the challenges


DCVMN Annual General Meeting

4 November 2020

# Context: only 10 months into the pandemic, **>46 M people known to have been infected & 1.2 M people have died**

Northern hemisphere enters flu season already suffering 2<sup>nd</sup> wave.

- rate of new cases doubled in Oct, reaching **500,000/day**
- Europe enters 2<sup>nd</sup> lockdown



# Launch of the Access to COVID-19 Tools Accelerator

24 April 2020 co-hosted live event



## With:

- UN Secretary-General
- Heads of State & Government
- Head of Agencies, Academia
- Industry, CSOs, Foundations




# Access to COVID-19 Tools Accelerator (ACT)

2 over-riding objectives

- accelerate development of new diagnostics, treatments & vaccines
- achieve equitable global access to *all* COVID-19 tools

# ACT-A goal: to rapidly reduce risk of severe disease & end acute phase of pandemic




<sup>1</sup> targets primarily for LIC/LMICs


# ACT-A's bold structure is harnessing the international health architecture in an **unprecedented collaboration**

Deep engagement of Principals, integrated workplans & budgets, working with entire development system

 new partners, esp. UNICEF & NGOs are coming on board with a crucial role in implementation



# ACT-A's uses **accelerated & parallel workstreams** to rapidly achieve its goal



# ACT-A has already **achieved key landmarks**

(examples at 4 Nov 2020)



**new Rapid Tests** approved, with volume & price guarantees for LICs/LMICs (120m tests @ \$3-5/unit over 6 months)



**1<sup>st</sup> life-saving therapy** in rollout (Dexamethasone) with 3 M doses for LICs; **monoclonal antibodies** in evaluation for LICs



**COVAX Facility ‘in business’ with 186+** economies (>90% of world population); dynamic vaccine portfolio




**Equitable Allocation Framework & COVAX Allocation Mechanism** established




# ACT-A is helping to **save lives with these tools & accelerate other game changing products** in the coming months


Increasing disease severity




Pre ACT-A



by November



by March 2021



XXX New tool  ACT Accelerator  
ACCESS TO COVID-19 TOOLS

PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies

# But access to these critical tools differs widely across countries & could worsen without urgent financial & political action



**Prevent**  
*PPE use*



**Protect**  
*Vaccine deals*



**Test**  
*RDT/PCR use*



**Treat**  
*Dexa use*

*High Income*



*Low income*



Access level of tools

■ ■ ■ ■ ■ Rare    ■ ■ ■ ■ ■ Common

PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies

# ACT-A aims to **start changing the fundamental dynamic of the pandemic by March**



## Diagnostics

**Expanded testing globally:** with immediate increase in the number & volume of high-quality RDTs and facilitating their use



## Therapeutics

**Wider availability of treatments to save lives:** by accelerated use of Dexamethasone & oxygen and secured production capacities for mAbs



## Vaccines

**Full vaccination readiness:** with doses secured for global rollout to +20% of population; further R&D, tech transfer & capacity scale-out




## Health systems connector

**Best practice for delivering COVID-19 tools established and in roll out:** with rapid assessments, integrated delivery plans, large scale PPE use and key systems investments

# Political support is crucial for the **Equitable Allocation Framework & COVAX Mechanism** to deploy vaccines...

**Goal**


**Protect public health & minimize societal & economic impact by reducing COVID-19 mortality**



\*The fundamental principle applies that all countries receive doses at the same rate to the extent possible, notwithstanding likely practical limitations to be further worked out (e.g. minimum delivery volumes)

# ...and as ACT-A works to **close the urgent US\$4.5 B financing gap** for this near-term scale-up and impact

**Evolution of ACT-A funding need –\$US B**



**Urgent ACT-A financing gap per Pillar –\$US B**

Pillar	Gap (US\$ B)
Diagnostics	1.1
Therapeutics	0.75
Vaccines	1.0
HS Connector	1.7
<b>TOTAL</b>	<b>4.5</b>

1. incl. US\$ 0.1 B by Gavi for Vaccine Procurement/Delivery; 2. COVAX Facility manufacturing & procurement costs financed by self-financing participants (SFP) [List of SFPs](#)

"...if medical solutions can be made available faster and more widely relative to our baseline, it could lead to a cumulative increase in global income of almost \$9 trillion by end-2025"

*IMF World Economic Outlook, October 2020*

Addressing ACT-A's urgent needs = only **1 day** of that income and would save countless lives

## **ACT Accelerator:** moving from scale-up to impact

- **ACT-A is fully functioning & delivering results**
  - **Financial, political & operational challenges** increasingly threaten ACT-A's key objective of equitable allocation
  - **A major Advocacy Campaign** is ongoing to mobilize extraordinary financing (esp for urgent US\$4.5 B need)
  - **DCVMN has a crucial role to play** in addressing the challenges of equitable access to safe, efficacious & assured quality vaccine products for all countries
-